These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30238975)

  • 21. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges.
    Fancello L; Gandini S; Pelicci PG; Mazzarella L
    J Immunother Cancer; 2019 Jul; 7(1):183. PubMed ID: 31307554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy.
    Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Serizawa M; Maruyama K; Naruoka A; Akiyama Y; Urakami K; Kusuhara M; Mochizuki T; Yamaguchi K
    Cancer Sci; 2019 Aug; 110(8):2620-2628. PubMed ID: 31152682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
    Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
    Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
    Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application.
    McNamara MG; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E
    Cancer Treat Rev; 2020 Sep; 89():102084. PubMed ID: 32738738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.
    Kazdal D; Endris V; Allgäuer M; Kriegsmann M; Leichsenring J; Volckmar AL; Harms A; Kirchner M; Kriegsmann K; Neumann O; Brandt R; Talla SB; Rempel E; Ploeger C; von Winterfeld M; Christopoulos P; Merino DM; Stewart M; Allen J; Bischoff H; Meister M; Muley T; Herth F; Penzel R; Warth A; Winter H; Fröhling S; Peters S; Swanton C; Thomas M; Schirmacher P; Budczies J; Stenzinger A
    J Thorac Oncol; 2019 Nov; 14(11):1935-1947. PubMed ID: 31349062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay.
    Chaudhary R; Quagliata L; Martin JP; Alborelli I; Cyanam D; Mittal V; Tom W; Au-Young J; Sadis S; Hyland F
    Transl Lung Cancer Res; 2018 Dec; 7(6):616-630. PubMed ID: 30505706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor mutational burden on cytological samples: A pilot study.
    Pepe F; Pisapia P; Gristina V; Rocco D; Micheli M; Micheli P; Iaccarino A; Tufano R; Gragnano G; Russo G; De Luca C; Sgariglia R; Nacchio M; Girolami I; Eccher A; Russo A; Troncone G; Malapelle U
    Cancer Cytopathol; 2021 Jun; 129(6):460-467. PubMed ID: 33378102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing.
    Hatakeyama K; Nagashima T; Urakami K; Ohshima K; Serizawa M; Ohnami S; Shimoda Y; Ohnami S; Maruyama K; Naruoka A; Akiyama Y; Kusuhara M; Mochizuki T; Yamaguchi K
    Biomed Res; 2018; 39(3):159-167. PubMed ID: 29899191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
    Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
    BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.
    Sha D; Jin Z; Budczies J; Kluck K; Stenzinger A; Sinicrope FA
    Cancer Discov; 2020 Dec; 10(12):1808-1825. PubMed ID: 33139244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of tumor mutational burden with genomic alterations in Chinese urothelial carcinoma.
    Chen X; Ou Z; Wang L; Zhang Z; Fan X; Liu H; Wang W; Zhang Y; Zhu J; Liang X; Lou F; Cao S; Yao Y; Wang H; Yao X
    Mol Carcinog; 2022 Mar; 61(3):311-321. PubMed ID: 34729830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
    Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD
    J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benchmarking bioinformatics approaches for tumour mutational burden evaluation from a large cancer panel against whole-exome sequencing.
    Pang J; Xia H; Mi S; Zhang W; Pendrick D; Freeman C; Fernandes H; Mansukhani M; Hsiao SJ
    J Clin Pathol; 2023 Apr; 76(4):276-280. PubMed ID: 35906043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing.
    Heydt C; Rehker J; Pappesch R; Buhl T; Ball M; Siebolts U; Haak A; Lohneis P; Büttner R; Hillmer AM; Merkelbach-Bruse S
    Sci Rep; 2020 Jul; 10(1):11387. PubMed ID: 32647293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants.
    Pestinger V; Smith M; Sillo T; Findlay JM; Laes JF; Martin G; Middleton G; Taniere P; Beggs AD
    Mol Diagn Ther; 2020 Jun; 24(3):339-349. PubMed ID: 32306292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.